Effects of different opiate agonists on melanocyte-stimulating hormone release: in vivo and in vitro studies

Area of Science:

• Neuroendocrinology
• Peptide signaling

Background:

• Opioid peptides are known to modulate various physiological processes.
• Melanocyte-stimulating hormone (MSH) plays a role in pigmentation and other functions.

Purpose of the Study:

• To investigate the effects of specific opioid peptides on MSH secretion.
• To determine the dose-dependency and in vivo/in vitro characteristics of this interaction.

Main Methods:

• In vitro studies using cell cultures to measure MSH secretion in response to opioid peptides.
• In vivo studies to assess the effects of opioid peptides on MSH levels in a living organism.
• Dose-response experiments were conducted for Met-enkephalin, Leu-enkephalin, and beta-endorphin.
• Naloxone was used to investigate the opioid receptor involvement.

Main Results:

• All three opioid peptides (Leu-enkephalin, Met-enkephalin, beta-endorphin) were found to stimulate MSH secretion.
• In vitro, Met-enkephalin showed dose-dependent MSH release between 10-1000 ng/mL, and Leu-enkephalin between 10-100 ng/mL.
• Beta-endorphin induced MSH release at concentrations as low as 1 ng/mL, with a dose-dependent effect observed between 1-100 ng/mL.
• Naloxone, an opioid antagonist, successfully reversed the MSH-releasing effects of these peptides.
• The stimulatory effect of these opioid peptides on MSH release was confirmed in vivo.

Conclusions:

• Opioid peptides, including Leu-enkephalin, Met-enkephalin, and beta-endorphin, are potent stimulators of MSH secretion.
• The MSH-releasing effect is mediated through opioid receptors, as evidenced by naloxone's antagonistic action.
• These findings highlight a significant neuroendocrine link between the opioid system and MSH regulation.